Cargando…

Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy

Iceland was one of six European countries with an adjusted incidence of kidney replacement therapy (KRT) in 2018 lower than 100 per million persons (pmp), along with Estonia, Montenegro, Russia, Serbia and Finland. It was also one of 10 countries with an adjusted KRT prevalence <900 pmp. Furtherm...

Descripción completa

Detalles Bibliográficos
Autor principal: Ortiz, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217648/
https://www.ncbi.nlm.nih.gov/pubmed/35756737
http://dx.doi.org/10.1093/ckj/sfac074
_version_ 1784731696039460864
author Ortiz, Alberto
author_facet Ortiz, Alberto
author_sort Ortiz, Alberto
collection PubMed
description Iceland was one of six European countries with an adjusted incidence of kidney replacement therapy (KRT) in 2018 lower than 100 per million persons (pmp), along with Estonia, Montenegro, Russia, Serbia and Finland. It was also one of 10 countries with an adjusted KRT prevalence <900 pmp. Furthermore, the prevalence of chronic kidney disease (CKD) in Iceland is up to 2.44-fold lower and the death rate from CKD up to 3.44-fold lower than in other countries with a low incidence of KRT, suggesting that the low KRT incidence actually reflects a low need for KRT rather than low uptake or availability of KRT. This identifies Iceland as a benchmark for countries trying to reduce KRT incidence. Iceland also represents one of the best genetically characterized populations in the world, facilitating studies on the influence of the genetic background versus environment and lifestyle on CKD. This issue of CKJ reports the incidence and risk factors for CKD in Icelandic adults. Diabetes, acute kidney injury, hypertension, cardiovascular disease, chronic lung disease, malignancy and major psychiatric illness were associated with an increased risk of incident CKD, as were obesity and sleep apnea in women. However, in 75% of incident CKD cases, CKD was first detected in category G3 or higher, emphasizing the need for new tools that allow an earlier diagnosis of CKD that precedes the loss of >50% of the functioning kidney mass and/or wider use of albuminuria as a screening tool. The European Society of Cardiology just recommended assessing albuminuria for routine cardiovascular risk workups for all.
format Online
Article
Text
id pubmed-9217648
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92176482022-06-23 Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy Ortiz, Alberto Clin Kidney J Editorial Comment Iceland was one of six European countries with an adjusted incidence of kidney replacement therapy (KRT) in 2018 lower than 100 per million persons (pmp), along with Estonia, Montenegro, Russia, Serbia and Finland. It was also one of 10 countries with an adjusted KRT prevalence <900 pmp. Furthermore, the prevalence of chronic kidney disease (CKD) in Iceland is up to 2.44-fold lower and the death rate from CKD up to 3.44-fold lower than in other countries with a low incidence of KRT, suggesting that the low KRT incidence actually reflects a low need for KRT rather than low uptake or availability of KRT. This identifies Iceland as a benchmark for countries trying to reduce KRT incidence. Iceland also represents one of the best genetically characterized populations in the world, facilitating studies on the influence of the genetic background versus environment and lifestyle on CKD. This issue of CKJ reports the incidence and risk factors for CKD in Icelandic adults. Diabetes, acute kidney injury, hypertension, cardiovascular disease, chronic lung disease, malignancy and major psychiatric illness were associated with an increased risk of incident CKD, as were obesity and sleep apnea in women. However, in 75% of incident CKD cases, CKD was first detected in category G3 or higher, emphasizing the need for new tools that allow an earlier diagnosis of CKD that precedes the loss of >50% of the functioning kidney mass and/or wider use of albuminuria as a screening tool. The European Society of Cardiology just recommended assessing albuminuria for routine cardiovascular risk workups for all. Oxford University Press 2022-03-11 /pmc/articles/PMC9217648/ /pubmed/35756737 http://dx.doi.org/10.1093/ckj/sfac074 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Editorial Comment
Ortiz, Alberto
Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy
title Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy
title_full Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy
title_fullStr Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy
title_full_unstemmed Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy
title_short Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy
title_sort benchmarking ckd: incidence of ckd in a european country with low prevalence of ckd and kidney replacement therapy
topic Editorial Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217648/
https://www.ncbi.nlm.nih.gov/pubmed/35756737
http://dx.doi.org/10.1093/ckj/sfac074
work_keys_str_mv AT ortizalberto benchmarkingckdincidenceofckdinaeuropeancountrywithlowprevalenceofckdandkidneyreplacementtherapy